Four drug combination helps in lung cancer: U.S. study
By Maggie Fox, Health and Science Editor
WASHINGTON (Reuters) - Combining two chemotherapy drugs with two targeted therapies was safe and appeared to help patients with advanced lung cancer live longer, U.S. researchers reported on Thursday.
The combination of Roche and Co’s Avastin, ImClone’s Erbitux, carboplatin and paclitaxel appeared to add an average of two months to the lives of patients, from 12 months on average to 14 months, the team at the University of Texas M. D. Anderson Cancer Center said.